Dermata Therapeutics, Inc. (DRMA)

Total Valuation

DRMA has a market cap or net worth of $4.49 million. The enterprise value is -$5.16 million.

Market Cap	4.49M
Enterprise Value	-5.16M

Important Dates

The last earnings date was Wednesday, May 14, 2025, before market open.

Earnings Date	May 14, 2025
Ex-Dividend Date	n/a

Share Statistics

DRMA has 6.38 million shares outstanding. The number of shares has increased by 835.23% in one year.

Current Share Class	6.38M
Shares Outstanding	6.38M
Shares Change (YoY)	+835.23%
Shares Change (QoQ)	+49.99%
Owned by Insiders (%)	16.90%
Owned by Institutions (%)	1.69%
Float	4.15M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.58
P/TBV Ratio	0.62
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.70

Current Ratio	3.70
Quick Ratio	3.59
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -206.26% and return on invested capital (ROIC) is -131.08%.

Return on Equity (ROE)	-206.26%
Return on Assets (ROA)	-95.90%
Return on Invested Capital (ROIC)	-131.08%
Return on Capital Employed (ROCE)	-159.56%
Revenue Per Employee	n/a
Profits Per Employee	-$1.43M
Employee Count	8
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -81.63% in the last 52 weeks. The beta is 0.59, so DRMA's price volatility has been lower than the market average.

Beta (5Y)	0.59
52-Week Price Change	-81.63%
50-Day Moving Average	0.86
200-Day Moving Average	1.24
Relative Strength Index (RSI)	35.06
Average Volume (20 Days)	113,152

Short Selling Information

The latest short interest is 109,745, so 1.72% of the outstanding shares have been sold short.

Short Interest	109,745
Short Previous Month	255,045
Short % of Shares Out	1.72%
Short % of Float	2.64%
Short Ratio (days to cover)	0.41

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-11.65M
Pretax Income	-9.82M
Net Income	-11.46M
EBITDA	n/a
EBIT	-11.65M
Earnings Per Share (EPS)	-$4.24

Balance Sheet

The company has $9.72 million in cash and n/a in debt, giving a net cash position of $9.72 million or $1.52 per share.

Cash & Cash Equivalents	9.72M
Total Debt	n/a
Net Cash	9.72M
Net Cash Per Share	$1.52
Equity (Book Value)	7.30M
Book Value Per Share	1.21
Working Capital	7.30M

Cash Flow

Operating Cash Flow	-10.39M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

DRMA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-835.23%
Shareholder Yield	-835.23%
Earnings Yield	-251.23%
FCF Yield	n/a

Analyst Forecast

The average price target for DRMA is $3.00, which is 325.96% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$3.00
Price Target Difference	325.96%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on May 16, 2024. It was a reverse split with a ratio of 0.0666667:1.

Last Split Date	May 16, 2024
Split Type	Reverse
Split Ratio	0.0666667:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	1